🏛️ Verified NIH Record • Updated 2026-08-07
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis (NCT01892722)
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Novartis Pharmaceuticals
🩺 Plain-English Summary (8th-Grade Level)
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)
Who can join: Review the eligibility criteria below.
Location: UAB Childrens Hospital Harbor Center Neurology Dept — Birmingham, Alabama
Age range: 10 Years to 17 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (73 Sites)
Showing the first 25 of 73 sites.
- UAB Childrens Hospital Harbor Center Neurology Dept — Birmingham, Alabama
- Childrens Hospital Los Angeles — Los Angeles, California
- UCSF — San Francisco, California
- University of Miami — Miami, Florida
- AMO Corporation — Tallahassee, Florida
- Massachusetts General Hospital — Boston, Massachusetts
- Wayne State University — Detroit, Michigan
- Robert Wood Johnson Medical School — New Brunswick, New Jersey
- Childrens Hospital of Philadelphia — Philadelphia, Pennsylvania
- University of Utah Clinical Trials Office — Salt Lake City, Utah
- Novartis Investigative Site — Parkville, Victoria
- Novartis Investigative Site — Vienna,
- Novartis Investigative Site — Belo Horizonte, Minas Gerais
- Novartis Investigative Site — Rio de Janeiro, Rio de Janeiro
- Novartis Investigative Site — São Paulo, São Paulo
- Novartis Investigative Site — Goiânia,
- Novartis Investigative Site — Sofia,
- Novartis Investigative Site — Calgary, Alberta
- Novartis Investigative Site — Ottawa, Ontario
- Novartis Investigative Site — Osijek,
- Novartis Investigative Site — Tallinn,
- Novartis Investigative Site — Bordeaux,
- Novartis Investigative Site — Le Kremlin-Bicêtre,
- Novartis Investigative Site — Marseille,
- Novartis Investigative Site — Montpellier,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Sclerosis
- Deciphering Preserved Autonomic Function After Multiple Sclerosis — Rochester, Minnesota
- MSCopilot Users' Feedback in Real Life - Outcomes Regarding Integration in Patients' pathWay and Users' ExpeRience — New Orleans, Louisiana
- Reducing Fatigue in People With Multiple Sclerosis by Treatment With TENS — Boulder, Colorado
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis — Phoenix, Arizona
- A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) — Carlsbad, California
Explore by condition: All Multiple Sclerosis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.